Group items tagged

"I want it like I never dealt with 23andMe, which, as it turns out, is pretty much impossible - at least for the next decade."

"Our partner, Genome Medical, makes it easy for you to speak with a clinical professional about your DNA information. Interested in DNA testing but don't know where to begin? The experts at Genome Medical can help with that, too. Access your data files directly from your LunaDNA dashboard to support proactive health discussions. Help you better understand your genetic test results or help you determine if testing is right for you Explain your health risks based on your family and personal health history Offer guidance on how you can integrate your results into your health care Assess whether family members should consider genetic testing Within days from scheduling your phone or video appointment, speak with a board-certified genetic counselor who can: Genome Medical's genetic counselors do not analyze raw data from various DNA vendors, such as 23andme and AncestryDNA. However, they can answer any of your specific medical questions and determine if additional genetic testing is right for you and your family. SCHEDULE YOUR SESSIONASK A QUESTION SELF-PAY $99 AS LOW AS $50 With qualified insurance the cost for genetic counseling may be as low as $50 if the consultation is a covered service under your plan. © 2020 LunaPBC. All rights reserved. ABOUT US   LunaDNA was created by the Public Benefit Corporation, LunaPBC™, a team of passionate genomics and technology veterans. 2019 Technology Pioneers World Economic Forum SELF-PAY $99 AS LOW AS $50 With qualified insurance the cost for genetic counseling may be as low as $50 if the consultation is a covered service under your plan. SCHEDULE YOUR SESSIONASK A QUESTION HOW IT WORKSRESOURCES 2020 Most Innovative Companies Fast Company "

"Precise. Personalized. Prevention. Express your best DNA - the power to impact genetic expression is in your hands. Epigenetics is the study of how lifestyle & environment influence the expression of your genes." OUR MISSION is to empower and inspire providers and patients in optimizing genetic potential through precise, personalized protocols that positively impact patients' health and future generations.

"The Future of Health Depends on Your Data The first people-powered platform where you share health data, advance science and take part in the value created."

Dr. K's mentor "Lee Hood, MD, PhD, is a pioneer in the systems approach to biology and medicine. His research has focused on molecular immunology, biotechnology, and genomics. Dr. Hood began his career at Caltech, where he and his colleagues developed the DNA gene sequencer and synthesizer and the protein synthesizer and sequencer, which paved the way for mapping the human genome. A pillar in the biotechnology field, Dr. Hood has played a role in founding more than fourteen biotechnology companies, including Amgen, Applied Biosystems, Darwin, and Integrated Diagnostics."

"Is it ethical to edit your child's DNA - or your own? Does the answer depend on whether you're perfectly healthy or have a condition like vision loss or are dying of a degenerative disease? And does it matter whether you've got a PhD or never set foot in a college classroom?"

"BOSTON-Having exhausted the possibilities of the chromosome pairs that came preloaded on the original human genome, researchers at Harvard Medical School's Department of Genetics told reporters Wednesday they had unlocked 47 new editable genes following their purchase of a CRISPR expansion pack. "This add-on has a ton of incredible new genes, and we can't wait to start inserting them into our lab specimens," said Kevin Spiros, a professor of genetics, remarking that there was nothing more fun than having "some fresh strands of recombinant DNA to play around with." "

Abstract As biometric technology relies on bodily, physical information, it is among the more intrusive technologies in the contemporary consumer market. Consumer products containing biometric technology are becoming more popular and normalized, yet little is known about public perceptions concerning its privacy implications, especially from the perspective of human agency. This study examines how people perceive biometric technologies in different societal contexts and via different agents in control. Our study revealed that, in large part, people's perceptions of biometric technology are context-dependent, based on who retrieves and who benefits from the information and the situation where the data are collected. Participants were much more comfortable with more intrusive biometric technology in airport security than in a grocery store, and if it was employed to improve their health. We conclude by considering the implications of the survey for new threats to personal privacy that arise out of emerging technologies. Keywords biometric, facial recognition, DNA identification, digital privacy, digital data sharing, emerging technology, surveillance technology, contextual integrity, situational privacy

"Meet Sharon Terry, a former college chaplain and stay-at-home mom who took the medical research world by storm when her two young children were diagnosed with a rare disease known as pseudoxanthoma elasticum (PXE). In this knockout talk, Terry explains how she and her husband became citizen scientists, working midnight shifts at the lab to find the gene behind PXE and establishing mandates that require researchers to share biological samples and work together."

"Sitting in freezer at Boston Children's Hospital is a drug you won't find anywhere else. It's called milasen, and the 18 g that the hospital custom-ordered nearly 2 years ago should last for decades. That's because milasen was designed to treat a single patient-a now 8-year-old girl named Mila Makovec. Milasen was built on decades of work on a class of drugs called antisense oligonucleotides. But after Boston Children's Hospital scientist Timothy Yu diagnosed Mila with a never-before-seen genetic mutation, he took only 10 months to go from idea to injection. It's a record-shattering sprint in the typical drug-development marathon, and an unprecedented degree of personalization for a chemical drug."